Episode 36: ACR Response Criteria in Rheumatoid Arthritis Trials episode artwork

EPISODE · Mar 6, 2026 · 11 MIN

Episode 36: ACR Response Criteria in Rheumatoid Arthritis Trials

from QCast: Data-Driven Dialogue in Drug Development · host Quanticate

In this QCast episode, Jullia and Tom unpack ACR response criteria in rheumatoid arthritis clinical trials and why these endpoints are more operationally demanding than they look on paper. They explain what ACR20, ACR50, and ACR70 measure, how the responder definition depends on consistent joint counts, patient-reported assessments, and timely acute phase reactants, and why a clean-looking binary endpoint can still carry composite-style risks.Key TakeawaysProtect the core ACR components at site level, especially tender and swollen joint counts, visit windows, and lab turnaround, because missing or late elements can block endpoint classification.Build derivations and reporting to reflect the ACR hierarchy so ACR70 implies ACR50 and ACR20, avoiding avoidable inconsistencies in outputs.Plan early for how you will use repeated assessments, whether through repeated measures, curve-focused approaches, or overall summaries like weighted differences or GEE, and be clear on how results will be interpreted.🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.About QuanticateFounded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:Clinical Data Capture & ManagementBiostatistics & Statistical ConsultancyStatistical Programming & PK/PD AnalysisMedical Writing & PharmacovigilanceRegulatory & Submission SupportAI & AutomationPost-Marketing Safety & Real-World DataQuanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

Episode metadata supplied by the publisher feed · Published Mar 6, 2026

Embed this episode

In this QCast episode, Jullia and Tom unpack ACR response criteria in rheumatoid arthritis clinical trials and why these endpoints are more operationally demanding than they look on paper. They explain what ACR20, ACR50, and ACR70 measure, how the responder definition depends on consistent joint counts, patient-reported assessments, and timely acute phase reactants, and why a clean-looking binary endpoint can still carry composite-style risks. Key Takeaways Protect the core ACR components at ...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Episode 36: ACR Response Criteria in Rheumatoid Arthritis Trials

0:00 11:08

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of QCast: Data-Driven Dialogue in Drug Development?

This episode is 11 minutes long.

When was this QCast: Data-Driven Dialogue in Drug Development episode published?

This episode was published on March 6, 2026.

Can I download this QCast: Data-Driven Dialogue in Drug Development episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!